Cryoport, Inc.

Cryoport, Inc.

Cryoport, Inc. specialises in cryogenic logistics and temperature-controlled transport for the life‑sciences sector, supporting cell and gene therapies, biologics, vaccines and reproductive materials. The company provides specialised containers, monitoring technology and global shipping services designed to maintain ultra-low temperatures and regulatory traceability. Investors should note Cryoport’s growth is linked to the broader adoption of complex biologics, partnerships with biopharma and geographic expansion, but it faces execution, capital and competitive risks typical of a specialised logistics provider. Revenues can be recurring from contractual relationships, yet margins and cash flows depend on scale, utilisation and operational reliability. Regulatory oversight, supply-chain disruption and technological change are important considerations. This summary is for general educational purposes only and not personalised investment advice; values can fall as well as rise and prospective investors should assess suitability against their own circumstances.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Cryoport's stock with a target price of $13.22, indicating potential growth.

Above Average

Financial Health

Cryoport is showing strong revenue, cash flow, and profit margins, indicating solid financial performance.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring CYRX

Supply Chain Stocks: May Tariff Impacts Drive Growth?

Supply Chain Stocks: May Tariff Impacts Drive Growth?

The continued contraction of the U.S. manufacturing sector, heavily influenced by tariff wars, underscores the challenges facing domestic producers. This environment may create investment opportunities in companies that provide solutions for supply chain optimization and cost reduction.

Published: September 3, 2025

Explore Basket
The Plasma Profit Pipeline

The Plasma Profit Pipeline

Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.

Published: August 19, 2025

Explore Basket
Supplying The Grocery Wars

Supplying The Grocery Wars

Amazon is aggressively expanding its same-day fresh grocery delivery service, intensifying competition with rivals like Instacart and Walmart. This move creates a significant investment opportunity in the logistics, warehouse automation, and cold chain companies that support this large-scale fulfillment network.

Published: August 14, 2025

Explore Basket
The Froneri Effect: Investing In The Ice Cream Supply Chain

The Froneri Effect: Investing In The Ice Cream Supply Chain

Investment giant Goldman Sachs is acquiring a major stake in ice cream maker Froneri, signaling strong confidence in the consumer packaged goods space. This move creates a potential growth opportunity for companies supplying ingredients, packaging, and logistics to the expanding frozen dessert market.

Published: August 1, 2025

Explore Basket
Cell & Gene Therapy Logistics

Cell & Gene Therapy Logistics

This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Biologics cold chain

Demand for cell and gene therapies supports long‑term market growth, though commercialisation timelines and adoption can vary and affect revenue.

🌍

Global network expansion

Partnerships and international hubs can drive recurring revenues and scale benefits, but regulatory complexity and logistics risks remain.

Execution and competition

Scalability and operational reliability are critical; competition and capital needs can pressure margins, underscoring execution risk.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

CSX

CSX Corp.

CSX is a transportation company operating a freight rail system in the eastern United States

CNI

Canadian National Railway Company

Operates a railway network to transport passengers and goods in North America.

CHRW

CH Robinson Worldwide Inc.

CH Robinson Worldwide is a third-party logistics provider

Frequently asked questions